Crizotinib

Especificaciones

877399-52-5Número CAS

638-814-9Número CE

3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amineNombre IUPAC

C21H22Cl2FN5OFórmula química

450.3 g/molPeso molecular

Crizotinib; 877399-52-5; PF-02341066; (R)-crizotinib; PF-2341066; Xalkori; PF 2341066; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; PF 02341066; crizotinibum; PF2341066; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 53AH36668S; NSC-756645; CHEBI:64310; DTXSID701009329; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; 2-PYRIDINAMINE, 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]-; 3-((1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY)-5-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE; RefChem:57397; PF02341066; L01XE16; DTXCID601436157; MET Tyrosine Kinase Inhibitor PF-02341066; 638-814-9; Crizotinib (PF-02341066); 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; MFCD12407409; CHEMBL601719; Crizotinib (PF-2341066); C21H22Cl2FN5O; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; Xalkori (TN); Crizotinib [USAN]; Crizotinib [USAN:INN]; UNII-53AH36668S; VGH; 877399-52-5 (free base); Crizotinib (Standard); CRIZOTINIB [MI]; CRIZOTINIB [INN]; CRIZOTINIB [JAN]; CRIZOTINIB [VANDF]; CRIZOTINIB [MART.]; CRIZOTINIB [WHO-DD]; SCHEMBL93829; PF-2341066,Crizotinib; Crizotinib (JAN/USAN/INN); Crizotinib - Bio-X trade mark; GTPL4903; orb1223767; orb1307848; orb3141184; CRIZOTINIB [ORANGE BOOK]; Crizotinib, >=98% (HPLC); SCHEMBL29351506; SCHEMBL29622387; EX-A096; Crizotinib (PF-2341066)?; KTEIFNKAUNYNJU-GFCCVEGCSA-N; GLXC-04599; MSK10718; PF 2341066;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; BDBM50306682; EBC-12789; HY-50878R; NSC749005; NSC749769; NSC800080; AKOS015901233; AKOS015995207; CCG-264803; DB08865; FD20585; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; SDCCGSBI-0647655.P002; NCGC00250400-01; NCGC00250400-02; NCGC00250400-03; NCGC00250400-09; NCGC00250400-12; BC164334; BP-43636; HY-50878; C6935; NS00072165; SW202555-3; D09731; F793129; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; BRD-K78431006-001-10-2; BRD-K78431006-001-11-0; 877399-52-5, 877399-53-6 (acetate); Z2065417924; 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; (R)-3-[1-(2,6-Dichloro-3-fluorop henyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluoro-phenyl)ethoxy]-5-[1-(4-piperidyl)pyrazol-4-yl]pyridin-2-amine; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyra zol-4-yl]-2-pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamineSinónimos